Posts

Advisers to the U.S. Centers for Disease Control and Prevention (CDC) are meeting on Thursday to decide on the use of Moderna Inc.’s COVID-19 vaccine for children and adolescents aged 6 to 17, after months of delay in that age group due to safety concerns.

Moderna’s (MRNA.O) COVID-19 vaccine may have a higher risk of heart inflammation in young men than the Pfizer (PFE.N)/BioNTech (22UAy.DE) shot, according to data presented on Tuesday to U.S. Food and Drug Administration advisers weighing its use for those aged 6 to 17.

Advisers to the U.S. Food and Drug Administration will consider whether to recommend Novavax Inc.’s COVID-19 vaccine for adults, which the drugmaker hopes can become the shot of choice among some American vaccine skeptics.